163 related articles for article (PubMed ID: 8348073)
21. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL.
Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF
Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905
[TBL] [Abstract][Full Text] [Related]
22. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity.
Chilosi M; Semenzato G; Cetto G; Ambrosetti A; Fiore-Donati L; Perona G; Berton G; Lestani M; Scarpa A; Agostini C
Blood; 1987 Nov; 70(5):1530-5. PubMed ID: 3117133
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
Vedantham S; Gamliel H; Golomb HM
Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
[TBL] [Abstract][Full Text] [Related]
24. Lack of natural killer cell activity in hairy cell leukemia patients and partial restoration with interleukin-2.
Hooper WC; Barth RF; Shah NT
Cancer; 1986 Mar; 57(5):988-93. PubMed ID: 3484663
[TBL] [Abstract][Full Text] [Related]
25. [Effects of interleukin-2 and alpha and gamma-interferon on B cell colony formation in patients with hairy cell leukemia].
Ishiyama T; Abe S; Wakabayashi Y; Hirose S
Nihon Ketsueki Gakkai Zasshi; 1989 Aug; 52(5):880-6. PubMed ID: 2511715
[TBL] [Abstract][Full Text] [Related]
26. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
[TBL] [Abstract][Full Text] [Related]
27. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
28. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cell function and malignant cell phenotype in hairy cell leukaemia.
Ogmundsdóttir HM; Thorsteinsson L; Sigfússon A; Sveinsdóttir S; Björnsson S; Eyjólfsson G; Jóhannesson GM; Jensson O
APMIS; 1992 Jan; 100(1):10-20. PubMed ID: 1536717
[TBL] [Abstract][Full Text] [Related]
30. Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing.
Gastl G; Aulitzky W; Leiter E; Flener R; Huber C
Blut; 1986 May; 52(5):273-9. PubMed ID: 3635416
[TBL] [Abstract][Full Text] [Related]
31. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
32. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
33. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
34. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
35. alpha-Interferon inhibits spontaneous and induced DNA synthesis in hairy cell leukemia.
Hassan IB; Gronowitz JS; Carlsson M; Sundström C
Leuk Lymphoma; 1992 May; 7(1-2):69-77. PubMed ID: 1472934
[TBL] [Abstract][Full Text] [Related]
36. Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia.
Skotnicki AB; Wolska-Smolen T; Blicharski J; Zduńczyk A; Sasiadek U; Pituch-Noworolska A
Cancer Detect Prev; 1988; 12(1-6):511-22. PubMed ID: 3180143
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of human natural killer cell function by the combined effects of tumor necrosis factor alpha or interleukin-1 and interferon-alpha or interleukin-2.
Ostensen ME; Thiele DL; Lipsky PE
J Biol Response Mod; 1989 Feb; 8(1):53-61. PubMed ID: 2493514
[TBL] [Abstract][Full Text] [Related]
38. In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.
McKolanis JR; Ragab AH; Schmid DS
Arch Virol; 1991; 117(1-2):17-28. PubMed ID: 1848749
[TBL] [Abstract][Full Text] [Related]
39. Modulation of immune functions by long-term treatment with recombinant interferon-alpha 2 in a patient with hairy-cell leukemia.
Teichmann JV; Sieber G; Ludwig WD; Ruehl H
J Interferon Res; 1988 Feb; 8(1):15-24. PubMed ID: 3259251
[TBL] [Abstract][Full Text] [Related]
40. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
